Prayer and psychedelic substances have both demonstrated that they have antidepressant, analgesic and anxiolytic properties. This is in addition to showing that they can both induce alterations of mood and perception. Various studies using functional magnetic resonance imaging have identified cortical regions and brain structures that become active when individuals undergo intense spiritual experiences or are exposed to various psychedelic substances.
Spiritual retreat participants usually report enhanced spiritual well-being or improved sense of spirituality, which researchers think may be linked to changes in functional connectivity between regions in the brain that were actively involved in the production of those feelings.
A study that was conducted recently utilized functional magnetic resonance imaging to examine each participant’s brain before and during an intense spiritual retreat, which lasted a week. The study’s authors observed substantial changes in some regions in the brain, including the temporal lobe, the superior parietal lobe, the superior frontal lobe and the cingulate cortex.
A separate analysis conducted on different studies that used PET, fMRI and electroencephalography to study religions such as Islam, Buddhism and Christianity also found that some of the above regions in the brain were involved in spiritual or religious experiences. On the other hand, research on psychedelic substances has shown that most psychedelics stimulate the serotonin type 2A receptors in the frontal cortex.
Another study that looked into whether cingulate thickness could be used to forecast higher subjective ratings in the 5D Altered State of Consciousness test found a high number of serotonin 2A receptors in the cingulate cortex. This test is used to evaluate the peak alterations of consciousness. The four modes of consciousness include the integrative mode, the REM sleep mode, the deep sleep mode and the waking mode.
Additionally, an analysis of different studies that used SPECT, PET and fMRI imaging to investigate psychedelics such as mescaline, LSD, psilocybin, DMT and ayahuasca discovered that these drugs activated the temporal lobe, medial cortex, frontal lateral cortex and occipital cortex. Collectively, the findings of these studies propose that psychedelics and spiritual or religious experiences induce a generally positive mood and grow introspection by modulating brain activity.
It should be noted that these studies suggest that both experiences involve overlapping neural structures activating during hallucinations and intense religious experiences, and not that the experiences are identical, which is why it shouldn’t come as a shock that most cultures have established strict social and religious rules around the utilization of plants that induce hallucinations. Classical entheogenic plants or their symbolic representations have played a huge role in religious ceremonies in many indigenous communities for millennia.
The discovery that psychedelics activate a number of regions in the brain paints a promising picture for companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) that are taking steps to develop psychedelic remedies for neuropsychiatric disorders, including eating disorders.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
